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Abstract 
Neuroprotective effects of the active principles from selected Chinese 
medicinal herbs on p-amyloid-induced toxicity in PC12 cells 
HOI, Chu Peng 
Background: Alzheimer's disease (AD) is the leading cause of senile dementia, and one 
of the pathological hallmarks of A D is the neuronal degeneration associated with senile 
plaques. These plaques are composed of compacted amyloid P-peptide (Ap), a 39 - 43 
amino acid peptide derived from the endoproteolytic cleavage of amyloid precursor 
protein (APP). Deposition of soluble A p causes the aggregation of the peptide-forming 
amyloid fibrils, which have been shown to be neurotoxic both in vitro and in vivo. Thus, 
modulation of A p insult has been speculated to be a potential intervention therapy for A D . 
As Ap-induced toxicity is a well-established pathway of neuronal cell death in A D , 
cultured Ap-sensitive neuronal cell lines can be utilized as a primary screening tool for 
potential anti-Alzheimer's agents capable of protecting these cells upon exposure to Ap. 
In the present project, PC 12，an Ap-sensitive neuronal cell line derived from a 
transplantable rat adrenal pheochromocytoma, was employed to screen pure marker 
compounds from selected Chinese medicinal herbs for neuroprotective function. These 
herbs have been selected based on their documented benefits in the treatment of 
neurological diseases. 
Aim: The present project aimed to assess the anti-Alzheimer's therapeutic values of pure 
marker constituents from selected Chinese medicinal herbs through an investigation into 
their ability to protect PC 12 cells against AP-induced cytotoxic effect and the associated 
neuroprotective mechanisms. 
Methods; The effects of vitamin E (a reference antioxidant with neuroprotective 
function) and nine pure compounds from the selected herbs on neuronal cell death 
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induced by APmo in NGF-differentiated PC 12 cells were studied. An M T T conversion 
assay was used to determine cell viability for the control and treatment groups. The 
formation of reactive oxygen species (ROS) induced by APmo was evaluated by means of 
the fluorescent probe, 2',7'-dichlorofluorescein (DCF). Changes in intracellular free 
calcium levels ([Ca^ ]^,) in NGF-differentiated PC 12 cells induced by APmo were 
determined by the fluo-3 method. Caspase-3 (a key enzyme in the apoptosis 
cell-signalling cascade) activity induced by APmo in NGF-differentiated PC 12 cells was 
determined using fluorogenic caspase-3 substrate D E V D - A M C . 
Results: The results showed that exposing NGF-differentiated PC 12 cells to A(3mo (2.5 
fxM) induced a 63.1±2.6o/o decrease in M T T reduction after 24 h. Of all the ten 
compounds tested, only honokiol, magnolol and vitamin E were found to significantly 
increase the rate of cell survival. Further studies revealed that honokiol and magnolol 
could dose-dependently inhibit ApMo-induced generation of ROS, elevation of 
intracellular calcium level and activation of caspase-3. 
Conclusion: In conclusion, the present study is the first to demonstrate that the major 
active principles (honokiol and magnolol) from Magnolia Officinalis, a traditional 
Chinese medicine, significantly decreased AP-induced PC 12 cell death in vitro. Their 
neuroprotective effects are possibly mediated through reduced ROS production as well as 
























結果：結果顯示，當神經生長因子分化的PC12細胞暴露於APmq (2.5 ^M) 24小 
時後，將誘導MTT下降63.1±2.6%。在所有十個化合物中，僅honokiol, magnolol及 
VitaminE能顯著提高細胞的存活率。進一步的研究發現honokiol和magnolol以劑 
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1.1 Alzheimer's disease 
Alzheimer's disease (AD) is one of a series of mental disorders termed dementias 
("loss of mind" in Latin), which are characterized by cognitive and behavioural 
problems. A D is an age-related, irreversible and progressive neurological disorder that 
develops gradually and results in memory loss, behaviour and personality changes, 
impairment of activities of daily living as well as a variety of neuropsychiatric 
symptoms. The disease was named after Alois Alzheimer (1864 - 1915), a German 
neuropsychiatrist (Figure 1.1), by Emil Kraepelin in 1911. In 1906, Alzheimer first 
described a case study of a 51 -year-old female patient named Auguste D from 
Frankfurt (Alzheimer, 1907). The patient suffered from a progressive memory loss 
and disorientation, followed by language deficits, depression, auditory hallucinations, 
delusions, paranoia and psychosocial deficits. Auguste D eventually died in 1906 and 
her brain underwent a post mortem examination. The histopathological findings 
included cortical atrophy especially in the temporal and frontal lobe and the presence 
of two classical lesions, namely, amyloid plaques and neurofibrillary tangles, which 
are known today as the hallmarks of the Alzheimer's disease (Graeber et al., 1998). 
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Alzheimer's description of these histopathological lesions in conjunction with his 
clinical findings defined the disease from which his patient suffered. 
Figure 1.1 A photograph of Alois Alzheimer (Left) and his patient 
"Auguste D" (Right) 
1.1.1 Epidemiology and risk factors 
A D is the most frequent cause of dementia, accounting for 50-60% of all cases. It has 
posed a major public health concern due to its enormous impact on individuals, 
families, the health care system and the society as a whole. The prevalence of A D is 
below 1% in individuals aged 60-64 years but almost doubles for every 5-year age 
increment beyond age 65 and could exceed 50% after age 85 (Ferri et al., 2005). At 
present, it is estimated that approximately 4.5 million people suffer from this disease 
in the United States alone (Hebert et al., 2001). This number will continue to grow 
because of the anticipated dramatic increase in life expectancy and population of the 
elderly. For instance, there are about 360,000 newly diagnosed cases each year in the 
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us, and it is likely that the number of Americans affected by AD will dramatically 
increase to 16 million by the mid-century unless effective preventive treatments or 
drug therapies become available (Brookmeyer et aL, 1998; Hebert et al.，2000). This 
scenario applies not only to the U.S. but also worldwide. 
The dramatically increasing number of people suffering from A D and the costs 
associated with the disease have exerted a heavy economic burden on both individuals 
and the society. The costs associated with A D , including the loss in productivity, 
medical care, and personal caregiving expenses, are estimated to be at least $100 
billion per year, positioning A D as the third most expensive disease in the United 
States, after heart disease and cancer (Ernst and Hay, 1994). 
The most influential risk factor for the development of A D is increasing age (Qui et 
al., 2005). The second most important risk factor for A D is family history or genetic 
susceptibility. The overall genetic risk of developing A D appears to be linked to the 
presence of Apolipoprotein E (ApoE) genotype. Other well established potential risk 
factors include head trauma, low education background, low physical activity, female 
gender, obesity, diabetes, hypertension, hypercholesterolemia and atherosclerosis 
(Raber et al., 2004; Mortimer et al., 2003; Kivipelto et al., 2005). 
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1.1.2 Clinical manifestation and course 
A D is a progressive fatal neurodegenerative disease with certain characteristic clinical 
manifestations and neuropathologic features. It is characterized by an insidious onset 
and progressive impairment of multiple cognitive functions. In the early stage, the 
most prominent and initial symptom is the memory deficit notably an inability to 
leam new information or recall previously learned information. At this stage, memory 
impairment can be the only clinical finding and it is difficult to separate it from 
normal age-related amnesia. As the disease advances, other cognitive deficits become 
more apparent, including language disturbances (such as aphasia and paraphasia), 
executive dysfunctions (such as apraxia, poor planning, poor judgement and poor 
concentration), as well as visual-spatial and visual-constructive disabilities 
(disorientation and agnosia). Many patients will also display behavioural problems 
and psychotic symptoms such as depression, apathy, agitation, hallucination, delusion, 
verbal and physical aggression. Such impairments will result in difficulties with the 
activities of daily living (ADL). At the end-stage of the disease, the patients become 
rigid, mute, incontinent, bedridden and incapable of caring for themselves (McKhann 
et al. 1984; Hyman et al. 1989). 
The typical average survival rate of A D is 8 to 10 years from the onset of symptoms 
(Heyman et al., 1996; Wolfson et al., 2001). Recently it has been reported that the 
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median survival rate of 521 patients enrolled in a managed care organization was 4.2 
years for men and 5.7 years for women, which was about half of the previously 
predicted index (Larson et al, 2004). The course and rate of progression of A D varies 
from person to person. Increased age and greater severity of dementia lead to poor 
prognosis (Heyman et al., 1997). Eventually patients die of the complications 
associated with the disease. These complications are mostly linked to infectious 
diseases such as pneumonia and sepsis followed by myocardial infarction and stroke 
(Friedland, 1993; Beard et al., 1996). In the United States, A D ranges among the top 
ten causes of death in people aged 65 and over (National Vital Statistics Report, 
2002). 
1.1.3 Clinical diagnosis 
The diagnosis of A D is primarily dependent on clinical assessment, being based on a 
combination of medical history, physical and neurological examination, neuroimaging 
techniques, laboratory tests and neuropsychological assessment tools. One of the most 
widely used neuropsychological assessment tools for testing cognition is the Mini 
Mental State Examination (MMSE) (Folstein et al., 1975). The M M S E is an 
11-question questionnaire that evaluates five established domains of cognitive 
function: orientation, registration, attention and calculation, recall, and language. The 
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drawback of M M S E is that its accuracy may depend on age, education level and 
ethnicity of the individuals (Ylikoski et al., 1992; Clark et al., 1999). Thus, more 
accurate and reliable neuropsychological tests are being developed and validated. 
The clinical diagnosis of A D is essentially one of inclusion rather than exclusion, and 
it could be made by using established standardized clinical criteria, such as the 
National Institute of Neurological and Communicative Disorders and Stroke -
Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria 
(Table 1.2), the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV) (Table 1.1) (American Psychiatric Association 1994) and the International 
Classification of Diseases, 10th revision (ICD-10) (McKhann et al. 1984). Most 
dementias are commonly recognized with the use of the DSM-IV criteria which 
require the presence of multiple cognitive deficits in addition to the memory loss. 
However, the N I N C D S - A D R D A criteria can provide better specificity and accuracy 
and allow comparison between different research studies (Blacker et al., 1994; 
Gearing et al., 1995). The N I N C D S - A D R D A criteria categorize A D into three 
groups or types: possible A D (atypical clinical presentation of dementia), probable 
A D (typical presentation of dementia and the exclusion of other causes of dementia 
without histopathological confirmation) and definite A D (clinical diagnosis with 
6 
histopathological confirmation by autopsy or biopsy). The overall accuracy of the 
N I N C D S - A D R D A criteria for clinical diagnosis of A D is over 80% (Blacker et al., 
1994; Galasko et al., 1994). Disorders that may mimic or overlap with A D include 
depression, delirium, normal pressure hydrocephalus, dementia with Lewy bodies, 
vascular dementia, and frontotemporal dementia. 
Table 1.1 DSM-IV Diagnostic Criteria for A D 
Multiple cognitive deficits 
Short- and long-term memory impairment 
One or more of the following: 
Aphasia (language disturbance) 
Apraxia (impaired ability to carry out familiar tasks) 
Agnosia (failure to recognize familiar objects) 
Disturbance in executive functioning (planning, organizing, abstract thinking) 
Gradual onset, significant functional impairment, and continuous decline 
Decline from a previously higher level of function 
Exclusion of other possible causes 
No evidence for delirium. 
Source: Adapted from D S M - I V ™ , 1994. 
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Table 1.2 Selected N I N C D S - A D R D A Criteria 
Definite Alzheimer's disease 
Meets the criteria for probable Alzheimer's disease and has histopathologic evidence 
of Alzheimer's disease via autopsy or biopsy. 
Probable Alzheimer's disease 
Dementia established by clinical and neuropsychological examination and 
characterized by 
(a) progressive deficits in two or more areas of cognition, including memory; 
(b) onset between the ages of 40 and 90 years; 
(c) absence of systemic or other brain diseases capable of producing a dementia 
syndrome, including delirium. 
Possible Alzheimer's disease 
Dementia syndrome in the absence of other neurological, psychiatric, or systemic 
disorders sufficient to cause dementia; and in the presence of variation in the onset, 
presentation, or clinical course. 
Uncertain/improbable Alzheimer's disease 
Sudden onset; 
Focal neurological finding; 
Early seizure or gait disturbances. 
Source: Adapted from the report of the N I N C D S - A D R D A Work Group (McKhann, 
et al., 1984). 
1.1.4 Neuropathology and pathogenesis of AD 
The specific hallmark for the neuropathologic diagnosis of A D is the presence of both 
amyloid plaques and neurofibrillary tangles (NFT) within specific cerebral cortex and 
the limbic system (Goedert, 1993). The major constituent of the plaques is the 
amyloid P-peptide (Ap), which is derived from a large transmembrane protein 
encoded by a gene on chromosome 21, namely, the p-amyloid precursor protein 
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(APP), by the proteolytic activities of p-secretase and y-secretase (Kitaguchi et al., 
1988) (Fig. 1.2). The y-secretase produces p-amyloid peptides ending at different 
amino acid residues, e.g., valine4o (Ap40) or alanine42 (Ap42) (Hartmann, 1999). 
Neurofibrillary tangles are intraneuronal aggregates consisting of paired-helical 
filaments, which are the result of the deposition of the hyperphosphorylated 
microtubule associated with the protein tau (Hardy et al., 1998). There is mounting 
evidence supporting that the deposition sites of A p and N T F are located primarily at 
the entorhinal cortex and the hippocampus, a specific anatomic structure for memory 
coding and learning (Jellinger, 1991; Braak, H and Braak. E，1994). 
Extracellular P ^ ^ Intracellular 
NH.-I A P P B B I B W " H C O O H 
sAPPp ~n B B i t B I I 11 • ^ Muzzi 
Y-secretase y-secretase 
E I D I [ Z ^ — E Z Z ] 
Figure 1.2 Schematic diagram of APP processing. 
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It is now widely accepted that the production and aggregation of A P peptide is 
responsible for the pathogenesis of A D (Hardy et al., 2002). Specifically, the cerebral 
deposition of A p is the initiating and central event in A D pathogenesis and the rest of 
the pathological processes (such as N F T containing the tau protein, neuritic and 
synaptic injury, C N S neurotransmitters deficits) are secondary to the event of Ap 
deposition (Hardy et al., 1998, 2002). This view has been substantiated by a large 
body of evidence (Selkoe, 2001). First, Down's syndrome patients who carry an extra 
copy of chromosome 21 (i.e., an extra copy of APP gene) generate more A p and 
develop the clinical presentation of A D early in life (Glenner and Wong, 1984; 
Iwatsubo et al., 1995). Second, crossing APP transgenic mice with apolipoprotein E 
(apoE)-deficient mice leads to a decreased production of cerebral Ap in the offspring, 
indicating that the influence of apoE gene mutation is mediated through the A(3 
mechanism. Third, severe cerebral deposition of tau in N F T was found in 
frontotemporal dementia with parkinsonism but with no induced amyloid plaques 
characteristic of A D . Thus, the tau and N F T formation is likely to be secondary to Ap 
and plaque formation (Hardy et al., 1998). Fourth, the duplication of APP locus was 
found in five families with early-onset A D and resulted in abundant parenchymal and 
vascular deposition of Ap (Rovelet-Lecrux et al” 2006). 
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1.1.5 Drug therapy of AD 
There is currently no cure for AD; none of the currently available pharmacological 
treatments can stop the degenerative process of A D . The pharmacological therapy for 
A D can be divided into the following three categories. 
1.1.5.1 Drugs for symptomatic treatment 
The hypothesis of neurotransmitter disturbances in A D has led to the development of 
certain drugs for symptomatic relief. These agents are targeted at the restoration of the 
normal neurotransmitter level by replenishment or modulation methods. 
Acetylcholinesterase inhibitors (AChEIs) 
The acetylcholinesterase inhibitors (AChEIs) are currently the most effective 
therapeutic agents to delay the deterioration of A D . They can slow down the disease 
progression for a maximum of 24 months, as substantiated by the results of 
randomized controlled clinical trials. AChEIs that have been approved for the 
treatment of A D include tacrine (Cognex〜which is no longer used because of severe 
side effects), donepezil (Aricept^), rivastigmine (Exelon^), and galantamine 
(Reminyl^) (Knapp, 1994; Corey-Bloom et al., 1998; Rogers et al., 1998). These 
drugs are only modestly efficacious for improving the cognitive and neuropsychiatric 
functions in mild to moderate cases of A D and offer little or no benefit in the late 
stage of the disease (Farlow, 2002). 
Memantine 
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L-glutamate is the major excitatory neurotransmitter in the CNS, which is implicated 
in the learning and memory process through the N-methyl-D-aspartate ( N M D A ) 
receptor. In A D patients, increased glutamatergic activity can result in sustained 
low-level activation of the N M D A receptors and thus may impair normal neuronal 
function (Bormann，1989; Blanchard, 1997). Memantine is a non-competitive 
NMDA-receptor antagonist, which can protect neuron from glutamatergic 
excitotoxicity and preserve the cognitive function of hippocampal neurons. It was 
approved by the United States Food and Drug Administration (USFDA) for the 
treatment of moderate-to-severe A D in 2003 (Blanpied, 1997; Erdo and Schafer, 1991; 
Reisberg, 2003). However, according to a recent cochrane review (McShane et al” 
2006 )，there have not been any data to support the claim that memantine can offer 
beneficial effects in mild cases of A D . 
1.1.5.2 Drugs based on epidemiology 
Epidemiological data have substantiated the potential utility of certain drugs 
originally developed for other disease categories in the treatment of A D , some of 
which have been investigated in randomized clinical trials. 
Anti-inflammatory,Lipid-lowering agent and Hormone Replacement 
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Drugs that have been shown by epidemiological studies to possess potential 
therapeutic benefits to A D patients include nonsteroidal anti-inflammatory drugs 
(NSAIDs)，lipid-lowering agents (statins) and hormones (estrogen) for replacement 
therapy. Although the data suggested that the use of these medications may lower the 
likelihood of developing A D , clinical trial data to support their therapeutic use in 
patients with established A D are somewhat limited (Henderson et al., 2000; Mulnard 
et al., 2000; Scharf et al., 1999; Aisen et al., 2003; Rea et al., 2005). Much larger 
randomised controlled clinical trials with long treatment periods are currently 
ongoing. 
Antioxidants 
This therapeutic strategy is based on the oxidative injury hypothesis, which states that 
reactive oxidative stress plays an important role in the mechanism of Ap-induced 
neurotoxicity. Thus antioxidants or free radical scavengers might protect neurons 
from the downstream effects associated with the accumulation and toxicity of Ap. In 
vitro studies have shown that certain antioxidants such as vitamin E and selegiline can 
attenuate the neuronal injury induced by Ap (Behl et al” 1992). However, clinical 
evidence for such potential benefits is still limited. Several but not all epidemiologic 
studies have demonstrated that vitamin E can delay the onset of A D (Engelhart et al., 
2002; Zandi et al., 2004). A randomized controlled trial comparing the effect of 
13 
vitamin E and selegiline in A D patients showed that both drugs can maintain the 
functional status and slightly prolong the survival rate of the patients but have no 
effect on their cognition (Sano et al., 1997). 
1.1.5.3 Drugs with potential disease-modifying effects 
Advances in the molecular pathogenesis of A D have led to the development of novel 
drug candidates with potential disease-modifying capabilities, some of which are 
being tested clinically. Most of these promising agents are targeted at A p production 
or toxicity. 
Antiamyloid therapies 
Based on the amyloid cascade hypothesis, the major focus of A D treatment has been 
to inhibit brain's Ap production and aggregation, and to increase A p clearance from 
the brain. Several therapeutic strategies have been proposed, including secretase 
modulators, A p immunotherapy, Ap fibrillisation inhibitors, and anti-tau drugs. 
However, the potential utility of such antiamyloid therapies in A D treatment is still at 
the investigational stage. For instance, the clinical trial with Ap active immunisation 
was interrupted when encephalitis occurred in 6 percent of the patients (Orgogozo et 
al., 2003). The p- and 丫-secretase inhibitors are still in the preclinical or early clinical 
stage of development (Siemers et al., 2006). 
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1.1.5.4 Herbal supplements 
In traditional Chinese medicine practice, herbs have been commonly used to improve 
cognitive function and relieve the symptoms of A D . Some plants, such as ginkgo 
biloba, have shown statistically significant beneficial effects compared with the 
placebo group in A D patients in certain trials (Oken et al., 1998). Although these 
natural products appear to display multiple properties (e.g. anti-inflammatory, 
anti-oxidant, anti-amyloid activities), the exact mechanisms underlying their 
neuroprotective effects are still not well understood or adequately verified (Xiao et al., 
2002; Kim et al., 2001). Most of these agents are generally considered to be less toxic 
than western medicines. Consequently, there has been a tremendous surge in interest 
in the search for potential cures for A D from these herbs. A number of potential herbs 
for the treatment of A D are discussed next. 
1.2 Models for drug discovery in Alzheimer Disease 
The in vitro models that reveal the cellular and molecular pathways and the in vivo 
models that reflect the pathological hallmarks and clinical manifestation of the disease 
are both necessary for the development of new drugs for the treatment of A D . In the 
past decade, numerous in vitro and in vivo models for studying A D based on different 
15 
hypotheses have emerged. These hypotheses, which encompass the cholinergic 
hypothesis, amyloid cascade hypothesis, glutamatergic hypothesis, inflammatory 
hypothesis and oxidative injury hypothesis, are related to various types of 
pathophysiological events triggered in A D , which eventually lead to cellular 
dysfunction, neuronal death and clinical presentation. 
There is a large body of evidence supporting that the abnormal production and 
cerebral deposition of A p is the central causative factor in A D pathogenesis. Thus, 
therapeutic strategies aimed at reducing the level of Ap are currently a major focus in 
A D research. Animal, cellular, and molecular model studies have demonstrated that 
A D progression involves such cellular changes as inflammatory responses, 
mitochondrial dysfunction, oxidative injury, synaptic failure, and 
hyperphosphorylation of tau, all of which are secondary to the production and toxicity 
of AP (Hashimoto et al., 2000; Ivins et al., 1999). Therefore, the present thesis will 
only dwell on the in vitro and in vivo models based on the 'amyloid cascade' 
hypothesis. 
1.2.1 In vivo (animal) models 
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There are various mouse and rat models of A D that exhibit the pathological hallmarks 
as well as the clinical manifestations of the disease. 
Over a decade ago, animal models of A D were limited to developing a characteristic 
neuropathologic lesion or neurotransmitter deficit resulting in memory loss and 
behavioural abnormality by the use of neurotoxic agents or by mechanical destruction 
of the C N S structure. The majority of such models were targeted at the cholinergic 
(Smith, 1988; Hagan, 1994; Everitt and Robbins, 1997) and glutamatergic systems 
(Myhrer, 1993). However, these models essentially only mimic the symptoms rather 
than reflect the essential pathogenesis of A D , and thus are of limited utility in the 
development of potential disease-modifying therapeutic agents. 
Subsequently, improvement was made in these models to mimic the pathological 
hallmarks of A D pathogenesis by discrete C N S injection of Ap protein (Kosik and 
Coleman, 1992). Infusion of the rat's brain with a phosphatase 1 and 2A inhibitor, 
okadaic acid, has also been demonstrated to affect the formation of amyloid plaque 
and neurofibrillary tangle, as well as the presentation of cognitive impairment (Arendt 
et al., 1995). However, neither method gains any significant recognition and is 
rarely reported today (Mudher and Perry, 1998; Van D a m et al., 1998). 
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In recent years, the dramatic progress in the transgenic technology and the 
identification of specific genes responsible for A D pathogenesis has revolutionized 
the animal models of A D (Price et al., 1998; Wong et al., 2002). The first generation 
of transgenic mouse model of A D was nothing more than an expression of the 
wild-type human APP (hAPP) cDNAs gene, such as APPsw mouse (Tg2576) 
(Kalback et al., 2002). More recently, double transgenic mouse model, which 
expresses both the hAPP gene and human presenilin (PS) c D N A with a Familial 
Alzheimer's disease (FAD) mutation, has been developed (Borchelt et al., 1997; 
Holcomb et al., 1998). Although the transgenic mouse models of A D are very 
attractive, the generation and breeding of these mice is a time consuming, costly and 
labour intensive process. 
1.2.2 In vitro (cellular) models 
In vitro studies on A D have largely focused on the protection against Ap-induced 
toxicity in various cell culture systems (Park et al., 2002; Peng et al., 2002). These 
cell culture systems include both neuronal and non-neuronal cell lines, such as rat 
PC 12, SH-SY5Y, human NT2N, murine neuro2A and rodent primary cultures of 
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hippocampal neurons or cortical neurons. Presented next is a concise account of the 
features of these various cellular models. 
Rat PC 12 and human neuroblastoma (SH-SY5Y) cell lines attain some characteristics 
of the neuronal phenotype upon differentiation by nerve growth factor (NGF) (Peraus 
et al” 1997; Feng and Zhang, 2004). Although they cannot develop into polarized 
neurons and are thus unsuitable for probing the relationship between polarized sorting 
and APP metabolism, the partial neuronal phenotype and the advantage that these cell 
lines are easily grown in large quantities render them a very useful tool for drug 
screening as well as biochemical and molecular studies (Nordstedt et al., 1993). 
N T 2 N cells were originated from Ntera 2, which enjoys the features of C N S neuronal 
precursor cells after retinoic acid treatment (Pleasure and Lee, 1993). Although N T 2 N 
cells lack the properties of synaptic contacts, they can produce the proteins after 
plasmid transfection, and thus are a useful host for the generation of stable transfected 
neuronal cell lines (Pleasure et al., 1992). 
The primary culture of rodent hippocampal neurons has the advantage of developing 
synaptic contacts and dendritic spines, which enables the study of synaptic plasticity 
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and facilitates induction of LTP (Fletcher et al., 1991; Korkotian and Segal, 1999). 
Such characteristics are very important for the study of neurodegenerative diseases 
like A D . 
More recently, the application of viral transfection in neuronal cultures cell lines (such 
as neuroblastoma, N T 2 N cells and primary hippocampam neurons) has been 
successfully developed. However, the relatively limited quantities and high costs of 
these cell lines coupled with intensive labour involved have rendered them unsuitable 
for extensive screening experiments (Radford et al., 1998). 
In summary, the in vitro models of A D are useful for elucidating the molecular basis 
of the associated pathogenesis processes. It can be envisioned that with further 
refinement of the cellular models and a more in-depth understanding of the 
pathophysiological degenerative processes of A D , an effective and possibly curative 
therapeutic treatment for A D will soon become available. 
1.3 Chinese herbs for the treatment of AD 
Traditional Chinese Medicine (TCM) has been used for thousands of years and its 
effectiveness in the treatment of various diseases is well documented. There are a lot 
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of well-known cases where extraction, isolation and characterization of biologically 
active natural products from herbs have resulted in the development of novel effective 
drugs for use in Western medicine practice. In traditional Chinese medicine, 
numerous plants have been used to treat cognitive disorders, including 
neurodegenerative diseases such as A D . This section reviews some of the plants that 
have been used in traditional Chinese medicine for their reputed cognitive-enhancing 
or antiaging effects. Particular attention is given to those plants whose active 
principles possess pharmacological activities that may benefit the treatment of A D , 
including enhancement of cholinergic function in the central nervous system (CNS), 
anti-inflammatory and antioxidant activities as well as anti-amyloid effect. 
1.3.1 Ginkgo biloba L. 
Ginkgo (derived from the Chinese ‘Yin-Kuo，， meaning 'silver apricot，） biloba 
(referred to its two-lobed, fan-shaped leaves) is extracted from the leaf of the 
Maidenhair tree, which has existed on earth for tens of millions years. The earliest 
documented medicinal history of Ginkgo biloba can be found in the well-known 
China pharmacopoeia, called Chen Noung Pen T'sao, about 5,000 years ago (Gertz 
and Kiefer, 2004). In 1964，a Ginkgo biloba extract EGb 761 was successfully 
developed by a German pharmaceutical company for the European herbal drug market. 
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From then on, numerous studies had been conducted to evaluate the effects of Ginkgo 
in the treatment of A D during the pre-clinical and clinical stages. Although it is still 
unclear which ingredients in Ginkgo biloba are beneficial to the treatment of A D , 
many active constituents, including flavonoids and terpenoids, have been shown to 
display multiple neuroprotective effects both in vitro and in vivo. 
In cellular studies, Ginkgo biloba extract EGb 761 was reported to significantly 
attenuate reactive oxidative stress (ROS) in a neuroblastoma cell line expressing 
genes with AD-associated mutations (Smith and Luo, 2003). Ginkgolide B, a 
well-characterized constituent of Ginkgo, has also been extensively shown in vitro to 
be a platelet-activating factor (PAF) receptor antagonist, in addition to its ability to 
reduce the accumulation of free polyunsaturated fatty acid during ischemia and 
electroconvulsive shock in mice (Birkle et al., 1988). 
In animal studies, the muscarinic antagonist, scopolamine, has been used to induce 
cholinergic deficit resulting in memory impairment and other cognitive deficits in rats 
(Sunderland et al., 1985). G. biloba extracts have been found to palliate the severity of 
such scopolamine-induced amnesia in rats, enhance memory retention in both young 
and old rats, and improve short-term memory in mice (Chopin and Briley, 1992; 
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Petkov et al., 1993; Stoll et al., 1996), suggesting that the extracts exert their 
neuroprotective effects possibly in part by modulation of the cholinergic function. 
Further studies have demonstrated the clinical efficacy of G. biloba in A D patients. 
The EGb 761 extract has been shown to afford modest improvement in cognitive 
function among both A D and non-AD patients in some but not all studies, including 
randomised clinical trials (RCT) (Hofferberth, 1994; Le Bars et al., 1997). 
Considering its relatively few side effects and the aforementioned beneficial effects in 
A D patients, G. biloba remains a promising source of new A D drugs for further 
clinical assessment. 
Whether or not Ginkgo biloba exerts any direct anti-amyloid effect remains a subject 
of considerable debate. Some researchers reported that the Egb761 extract can protect 
hippocampal neurons against amyloid-beta-induced cell death (Bastianetto et al., 
2000). However, results from other laboratories appear to indicate otherwise 
(Dikalovet al., 1999). Yao and coworkers also demonstrated that ginkgolides 
prevented the P-amyloid-induced increase of ROS, but that did not rescue the cells 
from AP-induced apoptosis in cultured PC 12 cells (Yao et al., 1999). 
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In summary, the overall pharmacodynamic effect of Ginkgo biloba on A D is likely 
due to a combination of free radical scavenging activity, modulation of cholinergic 
function and platelet activating factor antagonistic effects. However, the direct 
anti-amyloid activity of Ginkgo biloba and its isolated compounds has yet to be 
ascertained. 
1.3.2 Magnolia officinalis 
The bark of the root and stem of Magnolia officinalis (Magnoliaceae) has been used 
in T C M to treat anxiety, headache and other nervous disturbances. For example, one 
study reported that the potential in vivo antidepressant effect of a T C M prescription 
(Banxia Houpu)，consisting of Pine Ilia ternata, Poria cocos. Magnolia officinalis, 
Perilla frutescens and Zinziber officinale (Luo et al” 2000). The biphenyl neolignans, 
honokiol and magnolol (Fig. 1.3), are the major compounds extracted from Magnolia 
offcinalis. Magnolol and honokiol constitute about 2.1% and 0.43% of the 
composition of the natural medicine respectively (Matsuda et al., 2001). Several 
previous studies have demonstrated the pharmacological activities of honokiol and 
magnolol, including antimicrobial activity, anti-plate let aggregation, 
anti-inflammation, and antioxidation (Wang et al. 1992; Chen et al., 2001). Their 
pharmacological activities in the central nervous system (CNS) such as sedation and 
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anxiolytic effect have also been reported (Kuribara et al., 2000). However, the exact 
mechanisms of action of honokiol and magnolol on the C N S remain unknown. 
OH OH OH 
^ \ ^ k 
(1) Honokiol (2) Magnolol 
Figure 1.3 Chemical structures of honokiol and magnolol 
Numerous studies have been undertaken to evaluate the effects and mechanisms of 
honokiol and magnolol in the control of neurologic disorders, especially 
neurodegenerative diseases. First of all, pharmacological activities associated with 
cholinergic function have been explored in an attempt to explain the reputed effects of 
Magnolia officinalis. Previous studies demonstrated that honokiol or magnolol can 
increase choline acetyltransferase (ChAT) activity and inhibit acetylcholinesterase 
(AChE) activity in vitro and may enhance in vivo hippocampal acetylcholine release 
(Hou et al., 2000). Other activities relevant to A D pathology have also been identified. 
The anxiolytic effects of honokiol and magnolol have been attributed to their ability to 
potentiate GABAergic neurotransmission (Kuribara et al., 1999, 2000; Squires et al” 
1999). Another study revealed that honokiol can protect rat brain from focal cerebral 
ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen 
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species production (Liou et al., 2003). However, whether or not honokiol and 
magnolol can protect the neurons from the toxicity of Ap is still unclear, and warrants 
further investigation. 
1.3.3 Acori graminei Rhizoma (AGR) 
Acori graminei Rhizoma (AGR), the dry rhizoma of Acorus gramineus Soland 
(Araceae), contains volatile oils, which are mainly a-asarone (8.8-13.7%) and 
p-asarone (63.2-81.2%) (Chang and But, 1986) (Fig. 1.4). 
OCH3 OCH3 
H OCH3 H OCH3 
(1) a-asarone (2) P-asarone 
Figure 1.4 Chemical structures of a-asarone and p-asarone 
A G R has been used clinically as a traditional Chinese medicine for treating stroke, 
A D or vascular dementia. It is commonly prescribed together with other Chinese 
herbs in traditional Chinese medicine practice for the treatment of stroke (Nishiyama 
et al., 1994b; Zhang et al., 1994). Previous studies have demonstrated a variety of 
pharmacological activities of A G R in the central nervous system, including the 
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abilities to produce sedation, decrease locomotor activity, increase 
pentobarbital-induced sleeping time, and attenuate apomorphine-induced stereotypic 
behaviour in mice (Vohora et al., 1990) as well as the actions on the central 
dopaminergic and G A B A systems (Liao et al., 1998). Recent studies have shown that 
A G R and its major component, asarone, exert a neuroprotective effect against 
excitotoxic neural death (Cho et al., 2000, 2002). In addition, Hsieh et al. reported 
cognitive enhancing effects of A G R on scopolamine-induced amnesia in rats (Hsieh et 
al., 2000). However, whether its major component, asarone, has any protective effect 
against the neural toxicity of Ap is still controversial. 
1.3.4 Gastrodia data (G. elata) 
Gastrodia elata (G. elata) has long been documented in the China Pharmacopoeia as 
a traditional Chinese medicine for treating headaches, dizziness, tetanus, epilepsy, 
convulsion and other C N S disorders (Huang, 1985). The potential beneficial C N S 
effects of this herb in disease treatment had been demonstrated in a good number of in 
vivo animal studies over the past two decades. Aqueous extracts of the herb were 
found to improve D-galactose-induced memory impairment in mice (Kao et al., 1994) 
and performance-deficit in senescent mice on the step-down passive avoidance task 
(Kao et al., 1995). The extracts also exhibited a significant scavenging effect on free 
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radicals (Liu and Mori, 1992, 1993). In addition, the extracts exerted an inhibitory 
effect on kainate binding to the glutamate receptor and offered protection against 
glutamate-induced cell death in IMR-32 human neuroblastoma cells, reflective of a 
potential anti-epileptic effect (Andersson et al., 1995; Hsieh et al., 1999; Lee et al., 
1999). Gastrodin (Fig. 1,5)，a major constituent of Gastrodia elata, is known to 
possess anticonvulsant effects (Baek et al., 1999). This constituent has been shown to 
improve amnesia induced by cycloheximide and apomorphine, but not acquisition 
impairment induced by scopolamine in rats (Hsieh and Wu, 1997). One recent study 
has revealed that the herb can prevent rat pheochromocytoma cells from 
serum-deprived apoptosis (Huang and Lin, 2004). All the above studies suggest that 
aqueous extracts of Gastrodia elata possess neuroprotective effects, which may be of 
benefit to the treatment of A D . However, whether gastrodin, the major component of 
this herb, can prevent the PC 12 cells from the insult of Ap has yet to be studied. 
OH 
OH 
Figure 1.5 Chemical structure of Gastrodin 
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1.3.5 Rhodiola rosea L.( R. rosea) 
Rhodiola rosea L, ("golden root ,，or "articroot", Crassulaceae) is the most common 
species of the genus Rhodiola and widely distributed in the Arctic region throughout 
Europe and Asia (German et al., 1999). This plant has been extensively used in 
traditional Tibetan medicine and has been a reputed remedy for treating fatigue and 
stimulating the nervous system. For this reason, Rhodiola rosea was first marketed as 
an "adaptogen" in the western countries (Germano et al., 1999). In recent years, R. 
rosea has received considerable attention in the scientific community owing to its 
numerous biological activities such as antioxidant, anti-depressant, anti-cancer, 
antimicrobial, and memory enhancing effects (Yoshikawa et al., 1997; Furmanowa et 
al., 2002; Petkov et al., 1986). 
The major active principles of Rhodiola rosea L. are believed to be the glycosidic 
compounds isolated from the plant and its callus culture extracts. Previous work has 
demonstrated that salidroside (Fig. 1.6), a key component of Rhodiola rosea L, can 
act as an antioxidant and a neurostimulant (Furmanowa et al., 1998; Sokolov et al., 





Figure 1.6 Chemical structure of salidroside 
1.3.6 Scutellaria baicalensis 
Scutellaria baicalensis is a valuable traditional Chinese medicinal herb that has been 
used for centuries to treat allergic and inflammatory diseases. The major active 
ingredients in Scutellaria baicalensis are believed to be polyhydroxyflavonoids such 
as baicalin (5,6,7-trihydroxyflavone-7-0-B-D-glucopyranosideuronic acid; Fig. 1.7) 
and its aglycone baicalein (5,6,7-trihydroxyflavone) (Nakamura et al., 2003). The 
potential antioxidant, free scavenging and anti-inflammatory activities of these 
flavonoids have also been established (Gao D et al., 1996; Gao Z et al., 2001; Huang 
et al., 2006). However, it is still not certain whether these flavonoids have any 
protective effects on Ap-induced neurotoxicity. 
O OH O 
HO OH 
Figure 1.7 Chemical structure of baicalin 
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1.3.7 Curcuma longa L. (Zingiberaceae) 
Curcuma longa L is a genus in the plant family of Zingiberacea and cultivated 
mainly in Asiatic countries, notably India and China. Traditionally, curcuma has been 
commonly used for treating wound, hepatic disorder, coryza, inflammation, 
rheumatism and tumor (Li, 1977; A m m o n et al., 1991). 
The yellow pigmented fraction of Curcuma longa contains three major curcuminoid 
constituents, namely, curcumin, demethoxy curcumin, and bisdemethoxy curcumin 
(Fig. 1.8). Among them, curcumin is considered the most important active ingredient 
responsible for the biological activity of turmeric (Joe et al., 2004; Kim et al., 2003). 
As substantiated by a large volume of in vitro data, curcumin possesses antioxidant, 
anti-inflammatory, and anti-amyloid activities (Mukhopadyay et al., 1982; Ruby et al., 
1995; Kim et al., 2001). The compound also displays beneficial neuroprotective 
effects for the treatment of A D in several animal models of the disease. For instance, 
Lim et al. reported that curcumin decreased the cerebral deposition of A(3 in an 
Alzheimer transgenic APPsw mouse model (Tg2576) (Lim et al., 2001). Following 
these preclinical studies, several clinical trials for assessing the efficacy of curcumin 
in the treatment of A D are currently underway. One such study (a 24 weeks, phase II, 
double-blind, placebo controlled study) examines the safety and tolerability of two 
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doses of curcumin C3 complex versus placebo in patients with mild-to-moderate A D 
(Ringman et al., 2005). 
OH 
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(c) bis-demethoxycurcumin 
Figure 1.8 Chemical structures of curcuminoids: (a) curcumin; 
(b) demethoxycurcumin; (c) bis-demethoxycurcumin. 
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1.4 Aims of the study 
The exact role of P-amyloid accumulation in the disease progression is a central 
question in A D research. Based on the amyloid cascade hypothesis, counteracting the 
neurotoxicity of A p has been the main focus in the development of anti-Alzheimer's 
drugs. Thus, the main aim of the present Master's thesis was to explore the potential 
of the active principles (a-asarone, p-asarone, salidroside, baicalin, magnolol, 
honokiol, gastrodin, (-)-bilobalicle, curcumin) from selected Chinese herbs (Aeon 
graminei Rhizoma, Rhodiola rosea L.，Scutellaria baicalensis , Magnolia officinalis, 
Gastrodia elata, Ginkgo biloba L’ Curcuma longa L.) as anti-Alzheimer's agents 
through an investigation of their possible neuroprotective effect and associated 
mechanisms. 
Specifically, the objectives of present study are two-fold: 
1) To develop an in vitro model based on NGF-differentiated PC 12 cells for 
screening the ability of the pure active constituents to protect the cells against 
Ap-induced toxicity; and 
2) To investigate whether the reactive oxygen species (ROS), calcium 
homeostasis and neuronal apoptosis are mechanistically involved in the 
Ap-induced neurotoxicity in PC 12 cells. 
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Chapter Two 
Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Honokiol and magnolol were purchased from Wako Pure Chemical Industries (Los 
Angeles, V A , USA). (-)-Bilobalide from Ginkgo biloba leaves, vitamin E 
((+)-a-Tocopherol), a-Asarone, P-Asarone, baicalin, paraformaldehyde powder (95%), 
Triton R X-100, and propidium iodide (PI) were purchased from Aldrich Chemical 
Co. (Milwaukee, WI, U S A ) unless otherwise stated. Gastrodin and salidroside were 
purchased from the National Institute for the Control of Pharmaceutical and 
Biological Products (NICPBP, Beijing, China). Beta-amyloidi.40 (APi-40), 
beta-amyloid25-35 (AP25-35), scrambled beta-amyloid 1.40 (scrambled APi-40)，scrambled 
beta-amyloid25-35 (scrambled AP25-35) and EnzoLyteTM A M C Caspase-3 Assay Kit 
were supplied by AnaSpec Company (San Jose, CA, USA). 
[3-(4,5)-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium (MTT) and 
2\1 '-dichlorofluorescein-diacetate (H2DCF-DA) were purchased from Sigma 
Chemical Co. (Saint Louis, M O , USA). Fluo-3 A M was purchased from Molecular 
Probes, Inc (Eugene, OR, USA). All chemicals and organic solvents were of 
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analytical or high performance liquid chromatography (HPLC) grade, and all water 
used was deionized and double-distilled. 
2.1.2 Materials for cell culture 
Rat pheochromocytoma cells (PC 12 cells) were obtained from the American Type 
Culture Collection (ATCC, C R L 1721). Nerve growth factor (NGF) was purchased 
from Gibco B R L (Carlsbad, CA, USA). Dulbecco's modified Eagle's medium 
(DMEM), fetal bovine serum (FBS), horse serum (HS), 0.05% 
trypsin-ethylenediaminetetraacetic acid (EDTA), penicillin-streptomycin, and 
non-essential amino acids were obtained from GibcoBRL (Carlsbad, CA, USA) and 
Life Technologies (Grand Island, N Y , USA). Poly-L-lysine hydrobromide (25mg) 
was purchased from Sigma Chemical Co. (Allentwon, USA). The 96-well micro 
polystyrene plates (flat bottom) were purchased from Corning Costar Co. (NY, USA). 
All other materials for cell culture were supplied by Gibco B R L (CA, USA) and Life 
Technologies (Grand Island, N Y , USA). 
2.1.3 Instruments 
The optical density (O.D.) of each well was measured with a 96-well microplate 
spectrophotometer (Bio-Rad, Hercules, CA, USA). Fluorescence of the cells was 
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detected by a fluorescence microplate reader (Victor-2 Multilabel Counter, E G & G 
W A L L A C , Finland) and the microplate spectrofluorometer (Automed Multifunctional 
Monochromator Reader, Safire Tecan, Austria). Pl-stained PC 12 cells were examined 
by a Zeiss Axioskop fluorescence microscope (Zeiss Axioskop 2 Plus, Solent 
Scientific Ltd, United Kingdom). 
2.2 Methods 
2.2.1 Cell culture 
Rat pheochromocytoma cells (PC 12 cells) were obtained from the American Type 
Culture Collection (ATCC, C R L 1721) and were grown in Dulbecco's modified 
Eagle's medium ( D M E M ) supplemented with 5 % fetal bovine serum, 10% horse 
serum, 2 m M glutamine, 100 U/mL penicillin and lOOug/mL streptomycin at 37°C in 
5 % C02/95% air. PC 12 cells adhere poorly to plastic, and tend to grow in small 
clusters (Fig. 2.1). For this reason, the plates were precoated with poly-L-Lysine 
hydrobromide to enhance its adherence. Cells were removed from substrate by 
pipetting fresh medium over the cell sheet and gently shaking the flask. The cells were 
then aspirated in fresh medium with a small-bore pipette to break up clusters. A 
subcultivation ratio of 1:4 was used and the medium was renewed every 2 to 3 days. 
PC 12 cells were then seeded into the 96-well plates at a density of 1 x 
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lO^cells/lOO^l/well and allowed to adhere for 24 h at 37 PC12 cells were 
differentiated with 50 ng/ml N G F in D M E M . Five days after N G F addition, the 
medium was replaced with D M E M containing 50 ng/ml N G F with or without Ap, 
plus different concentrations of pure compounds. Ap fragment peptide was stored dry 
at -20°C, and was freshly prepared each time in double-distilled pyrogen-free water at 
a concentration of 500 )LIM. Each pure compound was suitably diluted in D M S O to 
different concentrations for neuroprotection testing. The final D M S O concentration in 
each sample was 0.1%, which was found in preliminary experiments to have no 
significant effect on the response under study. 
ATCC N u m b e r : CRL-1721 
_ _ 
Low Density Scai« Bar = lOOpm High Density Scale Bar» loopm 
Figure 2.1 Morphology ofPC12 cells {source: from ATCC) 
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2.2.2 MTT cell viability assay 
A methylthiazole tetrazolium ( [3-(4,5)-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide; M T T ) reduction assay was performed according to the method previously 
described by Mosman (1983). The M T T assay, which relies primarily on 
mitochondrial metabolic capacity of viable cells and reflects the intracellular redox 
state, has been widely used for measuring cell viability. After subjection to different 
treatment conditions and incubation durations, PC 12 cells were incubated with the 
M T T solution (final concentration, 1 mg/ml) for 3 h. The dark blue formazan crystals 
formed in intact cells were solubilized with lysis buffer (20% w/v sodium dodecyl 
sulphate in 50% v/v aqueous N,N-dimethylformamide with pH adjusted to 4.5). The 
optical density (O.D.) of each well was measured with a 96-well microplate 
spectrophotometer (Bio-Rad, Hercules, CA, USA) at 570 nm. The cell viability in 
response to the treatment with Ap peptide in the presence or absence of different 
concentrations of the tested compounds was calculated as percentage of cell viability 
二（O.D. treated/O.D. control) x 100. 
2.2.3 Characterization of the cytotoxicity of Ap peptide in NGF-differendated 
PC12 cells 
To determine the effective concentration and duration of Ap for inducing cell death, 
NGF-differentiated PC 12 cells were cultured with Ap at different concentrations and 
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for different durations. The cell viability was measured by the M T T conversion assay 
as described above. 
Ap-induced cell death in NGF-differentiated PC 12 cells was assessed using four 
different p-amyloid-related fragments (APi-40, scrambled APi_4o，AP25-35, scrambled 
AP25-35). The dose-dependent cytotoxic effect of each A p fragment on PC 12 cells was 
first evaluated by incubating the NGF-differentiated cells at various concentrations of 
the fragment (0.1，0.5, 1，2.5, 5, 10 |iiM) for 24 h and cell viability was measured by 
M T T assay. Similarly, the time-dependent cytotoxic effect of each fragment on PC 12 
cells was tested by exposing the NGF-differentiated cells to a fixed concentration of 
A p (2.5 \iM) for different durations (0，2，4, 6，24, 48 h) and the cell survival was 
assayed as before. 
2.2.4 Screening of the neuroprotective effect of major principles from selected 
herbs on PC12 cells against Ap-induced cytotoxicity 
PC 12 cells were incubated in aqueous culture medium containing 2.5 |iM Api.40 with 
or without the following tested principles: vitamin E((+)-a-Tocopherol), a-asarone, 
salidroside, baicalin, magnolol, gastrodin, (-)-bilobalide, honokiol，P-asarone, and 
curcumin. Each compound was dissolved and diluted in D M S O before addition to the 
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medium containing A p to yield different final concentrations (1, 12,5, 25, 50,100 
2.2.5 Measurement of reactive oxygen species (ROS) 
The formation of R O S was evaluated by means of the 2',7'-dichlorofluorescein (DCF) 
probe as described by Le Bel et al. (1992). Experiments were carried out in vitro using 
NGF-differentiated PC 12 cells that had been cultured for 5-7 days. 
T J'-Dichlorofluorescein-diacetate (H2DCF-DA) was added directly to the growth 
medium at a final concentration of 50 |liM and incubated for 1 H at 37°C. (H2DCF-DA 
is a non-fluorescent permeant molecule; it diffuses passively into cells where it is 
cleaved by intracellular esterases to form H2DCF which is thereby trapped within the 
cells. In the presence of intracellular ROS, H2DCF is rapidly oxidized to the highly 
fluorescent DCF.) Cells were then washed twice with phosphate buffered saline (PBS), 
then placed in fresh medium and treated with A p (2.5 jiM) or H2O2 in the presence or 
absence of different concentrations of the tested compounds for 24 hours. After 
treatment, cells were washed twice with PBS and the plates were placed in a 
fluorescent microplate reader (Victor-2 Multilabel Counter; Wallace 1420; E G & G 
W A L L AC). Fluorescence was monitored using an excitation wavelength of 490 nm 
and an emission wavelength of 520 nm. Results were means 士S.D. from four 
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independent experiments and expressed as the percentage increase in Relative 
Fluorescence Units (RFU) per well, which was calculated by the formula 
[(Ft24h-Fto)/Fto X 100] in the presence of A p or by the formula [(Ft3o-Fto)/Fto x 100] in 
the presence of H2O2，where Fto, Ft24h and Ftso are the fluorescence at time 0 hour, 24 
hour and 30min, respectively, 
2.2.6 Measurement of intracellular calcium levels 
Changes in intracellular free calcium levels in NGF-differentiated PC 12 cells 
were determined by the fluo-3 method (Aoshima et al., 1997; Kao et al.,1989; Wang 
et al., 2005). After exposure to Api.40 at different concentrations and for various 
durations in the presence or absence of different concentrations of the pure 
compounds, NGF-differentiated PC 12 cells were loaded with the Ca^^-sensitive 
fluorescent dye, Fluo-3 A M (5 fiM), at 37 °C for 30 min in culture medium and then 
washed free of extracellular Fluo-3 A M dye and resuspended in Krebs-Ringer-HEPES 
(KRH) buffer (131 m M NaCl，5 m M KCl, 1.3 m M MgS04，1.3 m M CaCb, 0.4 m M 
KH2PO4, 6 m M glucose, 20 m M HEPES, pH 7.4). Fluorescence was determined 
using a microplate spectrofluorometer (Automed Multifunctional Monochromator 
Reader, Safire Tecan, Austria) with excitation and emission wavelengths of 488 n m 
and 525 nm, respectively. Results were means 士S.D. from four independent 
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experiments and expressed as Relative Fluorescence Units (RFU) increased 
percentage relative to the reading at base line. 
2.2.7 Measurement of caspase-3 activity 
Apoptosis is characterized by the fragmentation of D N A and cleavage or degradation 
of several cellular proteins. The members of the caspase (CED-3/ICE) family of 
proteases have been implicated in certain biochemical events associated with 
apoptosis (Nicholson and Thornberry, 1997; Salvesen and Dixit, 1997). In particular, 
the activation of caspase-3 (CPP32/apopain), which has a substrate specificity for the 
amino acid sequence Asp-Glu-Val-Asp (DEVD) and cleaves a number of proteins, 
including poly(ADP-ribose) polymerase (PARP), DNA-dependent protein kinase 
(DNA-PK), protein kinase C (PKC)S and topoisomerases, has been proven to be 
crucial for the initiation of apoptosis (Nicholson and Thornberry, 1997). 
Caspase-3 activity was determined using a modified colorimetric assay as described 
by Ochu et al. (1998). The E n z o L y t e T M A M C Caspase-3 Assay Kit allows the 
detection of apoptosis by assaying the increases in caspase-3 activity. The assay is 
based on the proteolytic cleavage of 7-amino-4-methylcoumarin-derived substrate 
Z - D E V D — A M C (where Z represents a benzyloxycarbonyl group), which is weakly 
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fluorescent in the U V range (excitation/emission 〜330/390 nm), to a bright blue 
fluorescent product (excitation/emission 〜342/441 nm). 
Briefly, NGF-differentiated PC 12 cells were seeded at a density of 1 x loVells/100 
/well into 96-well plates and the tested compound (SOjul/well) was added with or 
without A p for the desired exposure time in a 37°C incubator. After treatment, 
capase-3 substrate solution (50 |Lil/well) was added to the cells. After reaction at 37°C 
for 30-60 min，the amount of aminomethylcoumarin ( A M C ) formed by proteolytic 
cleavage was measured using a microplate spectrofluorometer at an excitation 
wavelength of 360 n m and an emission wavelength of 460 n m (Automed 
Multifunctional Monochromator Reader, Safire Tecan, Austria). 
2.2.8 Propidium iodide (PI) staining to evaluate apoptosis and necrosis 
Propidium iodide (PI) fluorescent staining was performed to evaluate apoptosis and 
necrosis as described by Hayashi et al.(2004). [The dye, PI, identifies necrotic cells or 
cells in late stages of apoptosis as opposed to viable cells or cells in early apoptosis 
where the membranes are intact and PI is excluded. Nuclei of non-viable cells with 
damaged membrane will be stained red with PI, indicating that the dye has 
intercalated with cellular D N A (Fig. 2.2)]. 
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• 
Figure 2.2 PI fluorescent staining of PC 12 cells 
After various treatments for 24 h, the NGF-differentiated PC 12 cells were centrifuged 
at 1200 rpm for 5 min, then washed with phosphate-buffered saline (PBS) and fixed 
in 4 % paraformaldehyde in PBS for 15 min at 4°C. To detect apoptosis, cells were 
incubated with 0.2% Triton X-100 for 10 min at room temperature and then stained 
with 10 |Lig/ml DNA-specific binding dye PI (dissolved in 10 m M PBS solution) at 
37°C for 10 min. A 100 |LI1 aliquot of the Pl-stained PC 12 cell suspension was applied 
to a glass slide and dried at room temperature. The slide was visualized under a Zeiss 
Axioskop fluorescence microscope (Zeiss Axioskop 2 Plus, Solent Scientific Ltd, 
United Kingdom) with an Axiocam digital camera and the fluorescence module 
connected to a computer with Axio Vision software (Zeiss V4.0). The controls were 
used to analyze autofluorescence and any spontaneous neurodegeneration. 
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2.3 Statistics 
Results were expressed as the means 土 S E M from independent experiments. Data for 
the control and various treatment groups were analyzed by the analysis of variance 
( A N O V A ) for multiple comparison and the Bonferroni's post test for comparison 
between two different groups. A value of p < 0.05 was regarded as statistically 
significant. Effective concentrations (EC50) were determined by sigmoidal curve 
fitting of the data using GraphPad Prism Version 4.00 for Windows (GraphPad 




3.1 NGF-differentiated PC12 cells 
PC 12 cells were grown for 5~7 days in D M E M containing serum and N G F (50ng/mL) 
as previously described (Ito et al., 2003). Before cell differentiation by N G F , PC 12 
cells were round and tended to grow in small clusters (Fig. 3.1 A). Following 
treatment with N G F for 5〜7 days, the PC 12 cells exhibited neurite-like 
interconnecting processes (Fig. 3.1 B). 
H H ‘ 
(A) Before (B) After 
Figure 3.1 PC 12 cells before and after differentiation with N G F 
3.1.1 Determination of an appropriate cell density for the screening experiments 
Most experiments were carried out after the cells were seeded onto the 96-well plates. 
An appropriate cell density to be used in each of the 96-well plates was determined by 
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analyzing the relationship between the optical density and the cell count as shown in 
Figure 3.2. A density of 1 X lO* cells/well was selected since the change in optical 
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Figure 3.2 PC 12 cell density per well in 96-well plate 
3.1.2 Characterization of Ap-induced cytotoxicity in NGF-differentiated PC12 
cells 
To determine the appropriate concentration of and duration of exposure to Ap for 
inducing cell death, NGF-differentiated PC 12 cells were cultured with various 
concentrations of Ap for different durations. The toxicity of Ap in the 
NGF-differentiated PC 12 cells was assessed by the M T T assay. 
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3.1.2.1 Cytotoxicity of Ap-related fragments in the NGF-differentiated PC12 
cells 
Four different Ap-related fragments (APi.40, scrambled APmo, AP25-35, scrambled 
AP25-35) were tested for their toxicity in NGF-differentiated PC 12 cells (as shown in 
Figure 3.3). Although both A P M O (2.5 |LIM) and AP25-35 (2.5 |LIM), active fragments of 
Ap, afforded a significant decrease of M T T reduction activity (p<0.001), scrambled 
peptide of APmo or AP25-35 had no effect on the cell survival. 
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Figure 3.3 Inhibition of M T T reduction in NGF-differentiated PC 12 cells treated 
with 2.5 |xM APi.40, AP25-35, scrambled ApMo, scrambled AP25-35 for 24 
h. *** p<0.001 compared with the control (i.e., without Ap). 
3.1.2.2 Dose-dependent cytotoxic effect of Ap on PC12 cells 
As shown in Figures 3.4 and 3.5, when NGF-differentiated PC 12 cells were exposed 
to various concentrations of APmo (0.1, 0.5, 1，2.5, 5, 10 jiM) for 24 h, the M T T 
reduction rate was dose-dependently decreased, consistent with that reported by Ito et 
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al. (2003). Since no further M T T reduction was observed at APmo concentrations 
above 2.5 this concentration was employed in all subsequent experiments for 
assessing the APmo induced PC 12 cell damage. 
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Figure 3.4 Dose-dependent effect of Api.4o-induced cytotoxicity in 
NGF-differentiated PC12 cells for 24 h. (*** p<0.001 compared with 
the control group without Api.40) 
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Figure 3.5 Dose-response curve of APi-40-induced cytotoxicity in 
NGF-differentiated PC 12 cells for 24 h. 
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3.1.2.3 Time-dependent effect of Ap-induced toxicity in PC12 cells 
^ 1 6 0 � 
I 140 [ 
8 120 f x / ‘ ~ ~ _ _ + Control 
0 100 5 卒 
f 80 f V 
§ 6 0 A/31-40(2.5 
1 40 ** ^ uM) 
<u A A 氺氺氺 
^ 20 h *** 
E—< A I I I I I I I I 
0 6 12 18 24 30 36 42 48 
Time(hrs) 
Figure 3.6 Time course of APi_4o-induced cytotoxicity in NGF-differentiated PC 
12 cells measured by inhibition of M T T reduction. (*** p<0.001, ** 
p<0.01, * p<0.05 compared with the control group without APi.40) 
The time dependency of Ap-induced cytotoxicity in PC 12 cells was studied by 
exposing the NGF-differentiated PC 12 cells to a fixed concentration of APi.40 (2.5 juM) 
over a period of 48 h. As shown in Figure 3.6, the cell survival exhibited a slight 
elevation at the beginning due to the growth of the PC 12 cells. Thereafter the cell 
survival decreased with time and levelled off after 24 h. Therefore the protocol 
based on the 24 h exposure to 2.5 |LIM APi^O was employed in subsequent 
experiments. Such treatment conditions induced a 63.1±2.6o/o decrease in M T T 
reduction. 
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3.1.3 Protective effect of selected active principles against Api_4o-induced toxicity 
in PC12 cells 
M T T assay was used here to measure cell viability. PC 12 cells were incubated in 
culture medium containing 2.5 [iM APi-40 with or without the following principles: 
vitamin E ((+)-a-tocopherol), a-asarone, salidroside, baicalin, magnolol, gastrodin, 
(-)-bilobalide, honokiol, (3-asarone and curcumin. As shown in Figure 3.7, among the 
compounds tested, only honokiol, magnolol, curcumin and vitamin E showed 
significant protection of the PC 12 cells against the cytotoxic effect of Api.40. About 
36.9 + 2.6% of the PC12 cells survived after 24h treatment with 2.5 |iiM APi.40 and 
only honokiol, magnolol, vitamin E and curcumin were able to significantly increase 
the rate of cell survival (p<0.01). This effect appeared to be concentration-dependent 
and significant in concentration range from 1 |uM to 100 |LIM for the first three 
compounds. However, with curcumin, the protective effect was significant only up to 
a concentration of 50 |LIM. At the highest concentration (100 |LIM), honokiol and 
magnolol can increase the cell survival rate to attain over 95% and 80% of the control 
respectively. Further analysis revealed that the protective effects of honokiol and 
magnolol were significantly better than that of vitamin E (p<0.01 and p<0.05). In the 
same concentration range, however, the a-asarone, salidroside, baicalin, gastrodin, 
(-)-bilobalide, and p-asarone afforded no significant protection against the Ap-induced 
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toxicity in NGF-differentiated PC 12 cells. 
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Figure 3.7 Effect of selected principles on APi_4o-induced PC 12 cells death. PC 12 
cells were incubated in culture medium containing 2.5 |LIM A P M O with 
or without the following principles: vitamin E, a-asarone, salidroside, 
baicalin, magnolol, gastrodin, (-)-bilobalide, honokiol, p-asarone and 
curcumin. Cells surviving at 24 h were quantified by measuring their 
ability to reduce M T T and are expressed as % of control. Each data 
point represents the mean士 S E M of at least three separate experiments 
performed in quadruplicate each. (*** pO.OOl，** p<0.01, * p<0.05 
compared with the A P M O group which was treated with only 2.5 |LIM 
ABi.40； a a p<0.01， a p<0.05 compared with the vitamin E 
group) 
To compare quantitatively the neuroprotective effects of vitamin E, honokiol and 
magnolol, the effective concentrations (EC50) of these compounds were calculated. 
The relative efficacy of each principle was expressed on a 0-100% scale, where 0 % 
and 100% are taken respectively as the cell viability of the group treated with APi.40 
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alone (i.e., without the principle) and that of the control group (i.e., without A p and 
the principle; Fig. 3.8). The EC50 value of the tested compound is defined here as the 
concentration of the compound (|LIM) required to restore the cell viability to 50% of 
that of the control group (Fig. 3.8). 
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Figure 3.8 Relative efficacy of vitamin E，honokiol and magnolol on 
Api_4(rinduced PC 12 cells death. Each data point represents the mean士 
S E M of at least three separate experiments performed in quadruplicate 
each. 
Table 3.1 shows that honokiol and magnolol significantly protected the PC 12 cells 
from the insult of API.40 with EC50 values of 15.45±3.98 (|LIM) and 51.56 士 9.47 (|XM), 
respectively. 
53 
Table 3.1 The effective concentrations (EC50) of vitamin E, honokiol and 
magnolol in protecting PC 12 cells against APi_4o-induced toxicity 
Compounds EC50 * 士 SD ( ) 
Vitamin E 126.9 ±28.78 
Honokiol 15.45 ±3.98 
Magnolol 51.56 ±9.47 
* EC50 was computed by the sigmoidal curve fitting of the data as shown in Fig 3.8. 
3.2 Measurement of reactive oxygen species (ROS) 
3.2.1 Measurement of ROS induced by H2O2 
The level of R O S production in the PC 12 cells was determined using the fluorescence 
probe DCF. As a R O S standard for the D C F assay, hydrogen peroxide (H2O2) was 
employed to induce the formation of R O S (Wang and Joseph, 1999). As shown in 
Figure 3.9, an approximately linear concentration-response relationship was observed 
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Concentration-response curve of percentage increase of DCF 
fluorescence in PC 12 cells after 30 min exposure to various 
concentrations of H20 2. Each data point represents the mean data 
from five wells (n=5) with error bars representing the SEM. The line 
was obtained by linear regression and R2 depicts the coefficient of 
determination. 
Consistent with a previous report (Le Bel et ai. , 1992), the percentage increase of 
fluorescence was linearly correlated (R2=0.9707) with the concentration of H20 2 in 
the range between 50 J.lM and 500 J.lM. 
To determine whether vitamin E, honokiol and magnolol could prevent H20 2-induced 
ROS generation and the resulting oxidative stress, the PC 12 cells were pretreated 
with various concentrations (1, 12.5, 25, 50 and 100 J.lM) of the three compounds 
before exposure to 400 J.lM H20 2. As shown in Figure 3.10, the pretreated cells 
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Figure 3.10 Effect of honokiol, magnolol and vitamin E on H20 2-induced 
intracellular accumulation of ROS in PC 12 cells measured by DCF. 
Each data point represents the mean ± SEM of at least three separate 
experiments performed in quadruplicate each. (*** p<O.OOI, ** 
p<O.OI, * p<O.OS compared with the H20 2 group which was treated 
with 400 JlM H20 2 alone; 11 11 11 p<O.OO 1, compared with the control 
group) 
3.2.2 Measurement of ROS induced by AJ3 
By using the ROS-sensitive fluorescent dye, DCF, it was found that exposure of 
NGF-differentiated PCI2 cells to 2.S JlM A~1-40 for 24 h resulted in a 2.S fold increase 
(~2S6%) in DCF fluorescence. Incubation ofNGF-differentiated PCI2 with vitamin E, 
honokiol and magnolol (1, 10, SO, 100 JlM) inhibited significantly the Ap-induced 
increase in ROS accumulation in a dose-dependent manner (Fig. 3.11). 
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Figure 3.11 Effect of honokiol, magnolol and vitamin E on p-amyloid-induced (2.5 
| l i M A P i _ 4 0 ) formation of reactive oxygen species (ROS) measured by 
DCF after 24 h incubation. Results are the means 士 S E M of 4 
experiments performed in triplicate each. (*** p<0.001, ** p<0.01, * 
p<0.05 compared with the control group which was treated with 2.5 
}iM A B i . 4 0 , only; A A A pcO.OOl, A p<0.05 compared with the 
vitamin E group) 
3.3 Measurement of intracellular calcium levels 
Since the toxicity of aged APi.40 is possibly mediated in part through the elevation of 
intracellular calcium concentration (Mattson et al., 1993; Brorson et al., 
1995), the potential effects of vitamin E, honokiol and magnolol on the Ap-induced 
increase of were investigated. As shown in Figure 3.12, exposure of 
NGF-differentiated PC-12 cells to APi.40 (2.5 |a.M) for 24 h resulted in an approximate 
130% elevation of The effects of vitamin E, honokiol and magnolol were 
assessed at the same time point. All three compounds were found to significantly 
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reduce the Ap-induced elevation of in a dose-dependent manner. 
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Figure 3.12 Effect of vitamin E, honokiol and magnolol on P-amyloid-induced 
(Api_4o，2.5 jiM) elevation of intracellular calcium measured by Fluo-3 
method. Results are expressed as the means 士 S E M of 4 experiments 
performed in triplicate each. (*** p<0.001, ** p<0.01, * p<0.05 
compared with the control which was treated with only 2.5 )liM API.40) 
3.4 Measurement of caspase-3 activity 
It was speculated that the Ap-induced toxicity in PC 12 cells was associated with an 
activation of the capase-3 enzyme. In present study, the caspase-3 activity in the 
presence and absence of vitamin E, honokiol and magnolol was measured using the 
fluorogenic caspase-3 substrate D E V D - A M C (Tenneti et al., 1998). 
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3.4.1 AMC reference standard curve 
Prior to each experiment, an A M C fluorescence standard calibration curve was 
constructed as shown in Figure 3.13. This reference standard curve was used to 
calculate the amount of the capase-3 enzymatic reaction product formed. Excellent 
linearity in the curve within the A M C concentration range of 0-60 |uM (R^=0.9935) 
was observed. 
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Figure 3.13 A M C fluorescence standard calibration curve. Background correction 
to each sample reading (in relative fluorescence unit or RFU) was 
made by subtracting off the background reading, which was obtained 
by omitting A M C solution from the wells. Each data point represents 
the mean data from five wells (n=5) with error bars representing the 
SEM. The line was obtained by linear regression and R^ is the 
coefficient of determination. 
3.4.2 Measurement of caspase-3 activity. 
Figure 3.14 shows that the caspase-3 activity in the PC 12 cells was augmented to 
nearly 200% after incubation with 2.5 ^ M APi_4ofor 24 h (pO.OOl). When the PC12 
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cells were pretreated with honokiol or magnolol in concentration range of 1-100 jjJVI, 
the caspase-3 activity was significantly reduced in a dose-dependent manner (p<0.01) 
(Fig. 3.14). At the highest concentration (100 |LIM), honokiol and magnolol can reduce 
caspase-3 activity to nearly 110% and 100% of that of the control group. These results 
suggest that apoptosis in Ap-treated PC 12 cells is possibly mediated through 
caspase-3 activation, and the protective action of honokiol and magnolol may, at least 
in part, be attributed to an inhibition of the caspase cascade activity. 
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Figure 3.14 Effects of honokiol, magnolol and vitamin E on APi-40-induced 
caspase-3 activation measured by A M C assay. Results are expressed as 
the means 士 S E M of 4 experiments in triplicate. (AAA P<0.001 
compared with control; *** P<0.001, ** P<0.01, * P<0.05 compared 
with Ap group which is treated with only 2.5 ^ M AB1.40) 
3.5 PI staining for evaluating apoptosis and necrosis 
The PI fluorescent dye identifies necrotic cells or cells in late stages of apoptosis in 
contrast to viable cells or cells in early apoptosis which are not stained by PI due to 
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the intact cell membranes (Famer and Crisby, 2004). The relative amount of cells 
stained positive with PI was found to increase significantly in the PC 12 cells exposed 
to APi_4o (Fig. 3.15 B) relative to the control (Fig. 3.15 A). Unlike the cells treated 
with A(3i^o alone, very few cells were stained positive for PI after treatment with 
vitamin E, honokiol or magnolol alone (Figs. 3.16 A, 3.16 D and 3.17 A), as well as 
after pretreatment with vitamin E, honokiol or magnolol prior to exposure to Api_4o 
(Figs. 3.16 B and C, Figs. 3.16 E and F, and Fig. 3.17 B). However, the amount of 
Pl-stained cells were comparable for the PC 12 cells treated with either APi^o alone or 
together with the other tested compounds and for those cells pretreated with these 
compounds prior to APi一o treatment. 
• • 
(A) (B) 
Figure 3.15 PI staining of PC 12 cells. (A) Control treated with vehicle alone. 
(B) Cells exposed to APi.40 (2.5 |j.M) alone for 24 h. 
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Figure 3.16 PI staining of PC 12 cells. (A) Control treated with honokiol (100 ]iM) 
alone. (B) Cells pretreated with honokiol (100 )LIM) for 24 h prior to 
exposure to APi.40 (2.5 |xM). (C) Cells pretreated with honokiol (12.5 
\iM) for 24 h prior to exposure to APi.40 (2.5 |LIM). (D) Control treated 
with magnolol (100 fxM) alone. (E) Cells pretreated with magnolol 
(100 iiiM) for 24 h prior to exposure to A P m o (2.5 ^M). (F) Cells 





Figure 3.17 PI fluorescent staining of PC 12 cells. (A) Control treated with vitamin 
E (100 |LIM) alone. (B) Cells pretreated with vitamin E (100 |LIM) for 
24h prior to exposure to A P m o (2.5 |uM). 




4.1 AB-induced cytotoxicity in NGF-differentiated PC12 cells as an 
vitro model of Alzheimer's disease 
As alluded to before, the pathogenesis of A D is still unclear although the current 
thinking appears to be very much in favour of the amyloid cascade hypothesis. 
According to this hypothesis, an imbalance between the production and clearance of 
A p leads to deposition of A p in the brain and ultimately toxicity to the neurons (Van 
Hoesen and Hyman, 1990; Van Hoesen et al., 1991). As more and more evidence has 
accrued to support this hypothesis (Selkoe, 2001), the development of anti-amyloid 
therapeutic agents would seem to hold promise for treating the underlying cause of the 
disease. 
Despite the wide acceptance of the amyloid cascade hypothesis, there is still no 
perfect model that can completely reflect the characteristic pathological features and 
classical clinical manifestations of A D , primarily because of insufficient knowledge 
of the underlying pathogenesis and aetiology of the disease. However, since A p 
induced toxicity is a well-established pathway of neuronal cell death in A D , cultured 
Ap-sensitive neuronal cell lines could conveniently serve as a primary tool for 
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screening potential anti-Alzheimer's agents and an in vitro model for studying their 
underlying neuroprotective mechanisms. 
4.1.1 Cell line selection 
Rat phaeochromocytoma PC 12 cells were chosen for this study since they can 
acquire a neuronal phenotype after differentiation by N G F (Greene and Tischler, 
1976) and have proved to be the most sensitive cell line to Ap insult. In previous 
studies conducted elsewhere, the sensitivity of rat PC 12, rat primary cortical cultures 
and several human neuronal cell lines (SH-SY5Y, SK-NMC, and U-373MG) to Ap 
was evaluated by measuring the inhibition of M T T reduction after incubation with 
the peptide for a defined time period (Shearman et al., 1994). In these studies, the 
potency of A p in inducing cell death, as expressed by the inhibition of M T T 
reduction, was observed to vary with the cell types. Among them, the PC 12 cell line, 
either NGF-differentiated (50 ng/ml, 7 days) or undifferentiated, was the most 
sensitive to Ap-induced toxicity. Apart from such relative sensitivity to Ap-induced 
toxicity, the PC 12 cell line possess many other advantages over primary cultured 
neurons cells, including superior homogeneity of the cell population, and high 
susceptibility to both ROS-mediated cytotoxicity and calcium-dependent 
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homeostasis (Greene and Tischler, 1976). Thus, the present work employed the 
PC 12 cell line as an in vitro model to assess the cytotoxicity of Ap. 
4.1.2 Characterization of Ap-induced cytotoxicity in NGF-differentiated PC12 
cells 
The neurotoxicity of A p peptide to human neuron has been widely believed to play an 
important role in the pathogenesis of A D , and numerous reported studies have 
verified the cytotoxic effect of A p on cultured neurons (Bayer et al., 2001; C.W. 
Cotman and Su, 1996; Yao et al., 1999). As with previous reports (Shearman et al., 
1994), the present work has demonstrated an M T T reduction in PC 12 cells with A P m o 
and AP25-35 but not with scrambled Api.40 and scrambled AP25-35. Although the 
fragment 25-35 is normally defined as the active region of the A p peptide (Shearman 
et al., 1994), the Api_4o was employed in the current investigation for the following 
reasons. First, APi_4o is the predominant amyloid peptide found in human 
cerebrospinal fluid (CSF) and also the major species secreted from cultured cells 
(Asami-Odaka et al., 1995; Maho and Yasuo，2002). Second, the most prominent 
component of senile plaques in the brains of A D patients is APi^o rather than AP25-35 
(Funato et al., 1998; Morishima-Kawashima et al., 2000) Third, APi_4o forms 
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calcium-permeable channels in the cell membrane and readily induces subsequent 
membrane injury (Mattson et al., 1993). 
In agreement with a previous report, the present study has confirmed that exposure of 
NGF-differentiated PC 12 cells to APi.40 led to a dose- and time-dependent reduction 
in cell survival which levelled off after 24 hours of incubation (Ito et al., 2003). 
Therefore, all subsequent experiments employed an APi^o concentration of 2.5 jiM 
and a 24- hour incubation period to induce cytotoxicity in NGF-differentiated PC 12 
cells, 
4.2 Screening of the neuroprotective effects of selected active 
principles against Ap-induced cytotoxicity in NGF-differentiated 
PC12 cells 
Chinese herbal medicine has proved to be an invaluable source of medicinal natural 
products with multiple pharmacological actions for the treatment of a variety of 
diseases including cognitive disorders (Xiao, 1983). Historically, medicinal plants had 
been used to enhance cognitive function and to palliate symptoms associated with A D 
in traditional medicine practice (Carlini, 2003). Based on traditional clinical usage and 
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published data from animal experiments, medicinal plants may contain novel 
pharmacologically active compounds of potential benefits to the treatment of A D 
(Farnsworth, 1993; Nishiyama et al., 1992). 
To search for such anti-Alzheimer's agents, neuroprotection screening in the present 
study was conducted on nine pure marker compounds from several herbs which have 
been used in the treatment of senile dementia in traditional Chinese medicine practice. 
These compounds were honokiol and magnolol from Magnolia officinalis, a-asarone 
and p-asarone from Acori graminei Rhizoma , baicalin from Scutellaria baicalensis 
,gastrodin from Rhizoma gastrodiae, salidroside from Rhodiola rosea, (-)-bilobalide 
from Ginkgo biloba, curcumin from Curcuma longa L. Vitamin E is a well known 
antioxidant and free radical scavenger with demonstrated neuroprotective effect 
against Ap-induced toxicity in PC 12 cell (Behl et al., 1992), and was used here as a 
reference compound for comparison. 
In the present study, vitamin E exhibited a moderate but significant protection against 
p-amyloid induced neurotoxicity, consistent with the finding of Behl et al. (1992). 
Similarly, honokiol and magnolol could also protect the PC 12 cells from the cytotoxic 
effect of APi.40 in a concentration-dependent manner with EC50 values of 15.45±3.98 
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and 51.56士9.47 p M , respectively. Compared with vitamin E (£€50= 126.9 士 28.78 
|LIM), their protective effects were superior. Additionally, the effect of curcumin also 
appeared to be dose-dependent but only significant within the concentration range of 
1-50|LIM. At the highest concentration of curcumin (100|LIM) employed, the cell 
survival rate was only 35.65±2.27%, comparable to the group treated with APi.40 
alone. Such an abrupt abolishment of effect may be ascribed to the precipitation of 
the poorly water-soluble curcumin from the aqueous medium. In the same molar 
concentration range, however, a-asarone, salidroside, baicalin, gastrodin, 
(-)-bilobalide, and p-asarone did not show any significant protective effect against the 
AP-induced toxicity in the NGF-differentiated PC 12 cells. The lack of 
neuroprotective effect of (-)-bilobalide appeared to be in discordance with a few 
previous studies that lend support to the potential anti-amyloid effect of Ginkgo 
biloba extract (e.g., E G b 761) (Bastianetto et al., 2000). However, it is still 
controversial as to which component of the Ginkgo biloba extract is responsible for 
the reported anti-amyloid effect. One of these studies suggested that the major 
anti-amyloid and anti-apoptotic constituent in Ginkgo biloba was the ginkgolide B 
rather than the bilobalide (Jean et al., 1998), whereas another study showed that the 
bilobalide was the potential anti-amyloid component (Ahlemeyer et al., 1999). Such 
discrepancy could be attributed to the different types of cultured cells, different 
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isoforms of A p (e.g., AP25-35 or APi.40) and/or different research methodologies 
employed by different research groups. 
Honokiol and magnolol are two major constituents isolated from the stem bark of 
Magnolia officinalis, which has been traditionally used in the treatment of a number 
of neurological diseases (Watanabe et al., 1983). Previous studies have reported the 
potent antioxidant property of honokiol and magnolol (Lo et al., 1994). Several other 
studies have examined the neuroprotective effects of honokiol and magnolol against 
neuronal injury both in vitro and in vivo (Hou et al., 2000; Kuo et al., 2003). In 
addition, these two active components have been demonstrated to increase choline 
acetyltransferase activity, inhibit acetylcholinesterase, and promote 
potassium-induced acetylcholine release (Hou et al., 2000). However, to date, there 
has not been any investigation on the potential neuroprotective effects of these 
compounds using the PC 12 cell line model. The present work is the first to 
demonstrate the neuroprotective effect of honokiol and magnolol against Ap induced 
toxicity in PC 12 cells. 
While it is still not clear how the aggregated Ap peptides induce neurotoxicity, the 
following three main mechanisms may be involved: (a) Ap increases the formation of 
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reactive oxygen and nitrogen species, which appears to be an early event in the 
toxicity of many amyloid proteins; (b) perturbations of neuronal intracellular calcium 
homeostasis are observed in the presence of Ap; and (c) Ap induces apoptosis of 
neuronal cells. Thus, honokiol and magnolol may exert their potent neuroprotective 
effects via these mechanisms. 
4.3 Neuroprotection via inhibition of the ROS generation 
It has been proposed for many years that the production of oxidative stress is involved 
in the mechanism of the amyloid-induced cytotoxicity (Miranda et al., 2000a, b). 
Various assay methods have been used to verify the fact that Ap can cause an 
increased generation of reactive oxidative species (ROS) or other oxidative damage 
(Markesbery, 1997; Behl et al., 1999). The R O S generated by A p toxicity causes 
damage in the A D patient's brain through a series of mechanisms, including 
membrane lipid peroxidation, impairment of mitochondrial function and disturbance 
of cellular calcium homeostasis (Dyrks et al., 1992; Huang et al., 2000). Thus, 
antioxidation strategies have proved effective for the treatment of A D (Behl et al., 
1992; Cribbs et al., 1997; Pike et al., 1997; Daniels et al., 1998). 
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The R O S include hydrogen peroxide (H2O2), superoxide anion (O2") and hydroxyl 
radical (OH ), all of which are the by-products of the physiological or abnormal 
metabolic processes utilizing molecular oxygen. As a major precursor of ROS, H2O2 
has been widely employed as a free radical inducer to mimic an oxidative stress in in 
vitro models (Satoh et al., 1996). Therefore, to assess the role of R O S in the 
neuroprotection by honokiol and magnolol in the present study, the protective effect 
of the two compounds from the insult of H2O2 was first measured. The results 
revealed that honokiol and magnolol could significantly reduce the accumulation of 
R O S induced by H2O2 in PC 12 cells. This finding is consistent with the previously 
reported antioxidant properties of honokiol and magnolol (Lo et al., 1994). 
It has been previously reported that aggregated Ap deposited at the plasma membrane 
of cultured neurons led to the generation of free radical species (Mattson et al” 1993; 
Behl et al., 1992; Hensley et al., 1994). The present study has confirmed the previous 
work that the intracellular R O S increased in PC 12 cells after exposure to Api.40 and 
this change was reversed by antioxidant or free radical scavengers such as Vitamin E 
(Pereira et al” 1999). Moreover, the study has shown for the first time that both 
honokiol and magnolol reduced the production of R O S induced by APi-40 in a 
concentration-dependent manner. Since antioxidants are known to attenuate 
72 
Ap-induced oxidative injury, it is likely that the observed antioxidant properties of 
honokiol and magnolol may account for their beneficial effects in neuroprotection 
(Cash et al. 2002). 
4.4 Neuroprotection via suppression of calcium homeostasis 
The calcium hypothesis of A D was first postulated by Khachaturian (1989). There is a 
large body of evidence from experimental models supporting that the A p toxicity is 
manifested through the disturbance of calcium signalling (Mattson et al., 1992, 2000). 
The beta-amyloid has been described as interfering with the membrane permeability 
to calcium ion and regulation of calcium influx by the voltage-gated calcium channels 
and/or ligand-gated channels (Canevari et al., 2004; Ho et al., 2001; Rovira et al., 
2002). Previous work has shown that Ap-induced neurotoxic actions in PC 12 cells are 
associated with an elevation of [Ca^^], (Mattson, 2002). Therefore, the 
pharmacological manipulation of neuronal calcium homeostasis may serve as a useful 
therapeutic approach to the treatment of A D . 
The present study has confirmed the previous report that Ap induced an elevation of 
intracellular calcium in PC 12 cells and has also revealed that honokiol and magnolol 
suppressed the APi.4o-induced elevation of As reported elsewhere, both 
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honokiol and magnolol can block the external Ca^^ influx through depolarization 
and/or voltage-operated Ca^^ channels leading to a decrease in [Ca^ J^i in the rat uterus, 
and thus they may be considered as putative calcium channel blockers (Lu et al., 
2003). However, the exact mechanisms of these two compounds on calcium 
homeostasis remain unclear and require further investigation. 
The relationship between the alteration of calcium homeostasis and reactive oxidative 
stress in the mediation of Ap-induced toxicity is still controversial. There is 
compelling evidence to support that an Ap-induced disruption of calcium homeostasis 
may be due to a free radical-mediated process since this effect can be blocked by 
antioxidants (Huang et al., 2000; Zhou et al. 1996). Through this process, Ap-derived 
free radical products result in membrane lipid peroxidation and cellular dysfunction 
leading to the disturbance of calcium homeostasis (Hensley et al., 1994; Cribbs et al., 
1997; Miranda et al., 2000a, b). In contrast, alterations in calcium homeostasis might 
lie upstream in the cascade of Ap-induced injury and the oxidative injury might itself 
be calcium dependent (Castillo et al., 1997; Kruman et al., 1999; Janus et al., 2000). 
Increased intracellular calcium can result in an activation of the phospholipase A2 
enzyme and elevation of arachidonic acid level leading to an increased free radical 
production (Bonventre, 1992; Verity et al., 1994; Kihara et al., 1997). Regardless of 
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their exact relationship, the two aforementioned mechanisms can both lead to the final 
apoptosis of neurons as discussed next. 
4.5 Neuroprotection via inhibition of Ap-induced apoptosis 
4.5.1 Inhibition of caspase-3 activation 
There are multiple lines of evidence for Ap-induced neurotoxic and neuronal cell 
death being mediated through an apoptosis pathway (Martin and Liu, 2001; Troy et al., 
2001). Apoptosis is associated with the activation of a family of aspartic acid-specific 
cysteine proteases, known as caspases which exist as proenzymes until cleaved in 
response to apoptotic stimuli (Nicholson and Thomberry, 1997). In the caspase family 
consisting of more than 10 homologues, caspase-3 has been suggested to play a 
pivotal role in Ap-induced apoptosis in vitro (Harada and Sugimoto, 1999). For 
instance, increased level of caspase-3 was found in A D brains (Shimohama et al., 
1999). In addition, analysis of the neuronal apoptosis in the mice brain revealed a 
significant decrease in neuronal apoptosis in the brain of capase-3-deficient mice 
compared with the wild-type mice (Takuma et al., 2004). All these studies suggested 
that AP-induced neuronal death is mediated both in vivo and in vitro through the 
caspase-3 apoptotic cascade pathway. 
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In agreement with previous reports (Harada and Sugimoto, 1999), the present 
investigation based on A c - D E V D - A M C cleavage revealed a time-dependent 
activation of caspase-3, with the maximal increase occurring at 24 hr post-treatment 
with 2.5 |LIM of APi.40. However, when the neurons were pre-incubated with honokiol 
or magnolol, A pi.40-induced elevation of caspase-3 activity was remarkably inhibited 
at all tested time points, and the maximal inhibition was reached at 24 h 
post-treatment. Therefore, the inhibition of caspase-3 activity, which is critical at the 
execution phase of apoptosis, might have contributed to the observed neuroprotective 
effect of honokiol and magnolol, 
4.5.2 PI staining for evaluation of apoptosis and necrosis 
Cell death is widely believed to occur through two distinct processes: necrosis or 
programmed cell death called apoptosis (Nicotera et al., 1999). Several findings have 
suggested the involvement of necrosis in AP-induced neuronal death (Behl et al., 1994) 
while other reports are in favour of the prevalence of apoptosis in A D (Yang et al” 
1998). At present, it is likely that both mechanisms are overlappingly involved in cell 
death, and their relative contribution may depend on the strength of stimuli and the 
cell bioenergetic status. 
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To demonstrate the Ap-induced cytotoxicity, M T T assay was first performed in the 
present study. Since the M T T assay can only detect or identify the metabolic active 
cells in the culture, a histocytochemical analysis was performed using PI staining 
which identifies mainly the necrotic cells and cells in later stages of apoptosis. This is 
different from the detection based on the caspase-3 activation which occurs in the 
initiation and execution phases of apoptosis and thus represents the early 
physiological marker of apoptosis. By employing the caspase-3 activity measurement, 
M T T assay and PI staining technique together, a more complete picture on the 
Ap-induced apoptosis of neuronal cells can be obtained. 
In the present study, cell membrane damage was seen most remarkably in PC 12 cells 
incubated with APi.40. Many nuclei were positively stained by PL On the other hand, 
there were few positively stained nuclei in the cells without APi-40 stimulation 
(control). These data confirm the Ap-induced cytotoxicity in neuronal cells. By using 
PI staining, the present study clearly demonstrated that pretreatment of the PC 12 cells 
with honokiol and magnolol prior to exposure to APi.40 significantly reduced the 
amount of dying cells compared with those cells without the pretreatment. In 
summary, the above results coupled with the observed inhibition of caspase-3 activity 
77 




Conclusion and future work 
5.1 Conclusion 
In conclusion, the present study has demonstrated for the first time that the major 
active principles (honokiol and magnolol) from Magnolia officinalis, a traditional 
Chinese medicine, significantly decreased APi_4o-induced PC 12 cell death in vitro. 
Their neuroprotective effects are possibly mediated through reduction of R O S 
generation, suppression of intracellular calcium elevation and inhibition of caspase-3 
activation. 
These findings have important implications for the treatment of Alzheimer's disease, 
and could serve as a basis for further development of honokiol and magnolol into 
anti-Alzheimer's agents. 
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5.2 Future work 
Future studies should aim to address the questions raised and resolve the problems 
encountered in the present work. The following are some suggestions for future 
studies: 
1. The mechanisms responsible for the observed in vitro anti-amyloid effect of 
honokiol and magnolol are not well understood. Future work should consider 
other possible mechanisms that have not been investigated in the present thesis, 
including regulation of mitochondrial function, inhibition of nitric oxide 
production, and certain molecular signaling pathways such as signaling through 
the neuronal nicotinic receptor or N M D A receptor. 
2. The present study has only examined the neuroprotective effect of honokiol and 
magnolol against Ap-induced cell death in vitro. Future studies should focus on 
their anti-amyloid effects in vivo (with animal models). 
3. Since the brain is the major targeting site of anti-Alzheimer's agents, it would be 
worthwhile to investigate the blood-brain barrier permeability of honokiol and 
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